Concepedia

Dany Habr

DH

Statistics

Publications

44

Citations

3.7K

H-Index

30

Active since

2006

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

University College London

American University of Beirut

Cairo University

Dany Habr is an author at Novartis (United States) specializing in medicine, iron metabolism, and hematology.

ORCID

Top concepts

Publications per year

2006–2021

44

Publications

44

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer et al. · New England Journal of Medicine · 2015 · 851 citations

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

Maria Domenica Cappellini, John B. Porter, Amal El‐Beshlawy et al. · Haematologica · 2009 · 284 citations · Full text

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini et al. · Blood · 2009 · 194 citations

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

N. Gattermann, Carlo Finelli, Matteo Giovanni Della Porta et al. · Haematologica · 2012 · 170 citations · Full text

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Srđan Verstovšek, A. M. Vannucchi, Tamás Masszi et al. · Haematologica · 2016 · 156 citations · Full text

, , +15

1–5 of 44